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Teaser
You make the compounds you design. This article describes a new way for chemistry
undergraduates to learn about drug discovery through a series of lecture-workshops, target
compound design and laboratory work.
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Abstract
A practical drug discovery project for third-year undergraduates is described. No previous knowledge
of medicinal chemistry is assumed. Initial lecture-workshops cover the basic principles; then students
are asked to improve the profile of a weakly potent, poorly soluble PI3KG inhibitor (1). Compound
array design, molecular modelling and screening data analysis are followed by laboratory work in
which each student, as part of a team, attempts to synthesise at least two target compounds. The
project benefits from significant industrial support, including lectures, student mentoring and
consumables. The aim is to make the learning experience as close as possible to real-life industrial
situations. Forty-eight target compounds have been prepared, the best of which (5b, 5j, 6b and 6ap)
improved the potency and aqueous solubility of the lead compound (1) by 100-1000 fold and t10-fold,
respectively.
Introduction
This paper is an account of a hands-on drug discovery course that we have been running for the
past three years at the University of Nottingham. The purpose is five-fold: to teach students, who are
in the third year of a four-year MSci degree course, how new medicines are discovered; to give an
appreciation of the role of the chemist in that process; to give students practice in compound design
and data interpretation; to use industry-standard equipment and methods in the laboratory; and to
develop communication, team-working and inter-personal skills. Key aspects of the course were the
participation of scientists from GlaxoSmithKline (GSK) as lecturers and workshop mentors, and,
above all, in the practical application of drug discovery principles in the laboratory.
From GSKs perspective, the aim and guiding principle was to train industry ready graduates for
employment in medicinal chemistry by the pharmaceutical industry. In this context, industry ready
meant students who have been taught applied medicinal chemistry as practised in industry as
opposed to the less applied approaches usually found in academia. A substantial part of the course
is taught not by professional teachers but by enthusiastic professional medicinal chemists. This
provided an up to date perspective reflecting current industrial practice and science of drug discovery,
rather than a case history describing science and processes from the past.
The value of investigational or research-driven laboratory projects (of varying length and complexity)
has been discussed widely.
1-3
Advantages are that students feel more engaged, as projects are
aligned to real-life problems,
4
and there is not necessarily a right answer, as in real research.
Indeed, it has been shown that the type of laboratory work affects views on the nature of scientific
enquiry itself.
5
At the University of Nottingham, the first two years laboratory experience teaches
technique through following a set of traditional recipe-following laboratory experiments. By contrast,
those staying on to complete the MSci fourth year research project are in at the deep end, having to
comprehend primary literature, design experiments, and break new ground where uncertainty and
failure are everyday experiences. Consequently, we sought to bridge this gap by developing projects
6
that were positioned somewhere between the inquiry-led (students define the problem, design
experiments and analyse the data generated) and the research-based (working on a real problem
with potential to advance knowledge).
7,8
Another reason for embarking on this work was provided by an HEA Physical Sciences survey of
chemistry graduates in 2010.
9
The students were asked in retrospect to highlight skills deficits, i.e.
skills that the graduates wished they were proficient in, once employed. Top of the list were
experiment design, team working, oral presentations and time-management. Investigational projects
could give much needed experience in these areas.
Course description: Principles of medicinal chemistry, project background and target design.
The course and accompanying laboratory work constitute 10 credits each (students take 120 credits
annually; one credit corresponding approximately to 2 hours of lectures and an equivalent amount of
private study). No understanding of medicinal chemistry is assumed. The principles are taught
through five, two-hour workshops which follow a relatively conventional form  a brief description is
provided below. Assessment of this part of the module is through a 90 minute written examination.
x Introduction to the process of Drug Discovery  what it takes to discover a new medicine,
emphasising the role of the chemist. The discovery of salmeterol for the treatment of asthma
 a case history of drug discovery.
x Discussion of physicochemical properties (particularly logP and pKa). Basic principles of
pharmacokinetics and drug metabolism, including tactics for blocking metabolism. Lipid
crossing. Impact of acidity/basicity/lipophilicity on absorption and pharmacokinetics;
Lipinskis Rule of Five.
x Structure Activity Relationships and relation of structure to physicochemical properties.
Hydrogen bonding and polar surface area; size; lipophilicity and electronic effects of
substituents. Outlines of pharmaceutical properties (such as drug solubility and stability).
Drug structure and toxicity.
x Pharmacology: drug target and target classes. Receptor pharmacology
(agonists/antagonists). Enzyme inhibitors, with kinases as an example.
x Computational chemistry. Molecular interactions  how drugs bind to targets. Molecular
similarity  the basis of bio-isosterism. Conformations of molecules and how to calculate
them. Structure-based drug design.
After this, the course embarks on teaching skills in drug design. One workshop is used to introduce
the research-based part of the course, comprising a brief description of the target disease (asthma)
and the chosen therapeutic approach (kinase inhibition). Essential background on compound array
design and screening is also provided. The importance of team skills is discussed, and the way this is
approached is expanded upon later in this article. The students are placed in teams of six, each with
an experienced medicinal chemist as mentor, and are asked to design compounds that address the
deficiencies of a lead compound (1)(Figure 1). Three two-hour workshops are devoted to this. The
lead is a weakly potent (pIC50 = 5.7), lipophilic (clogP = 3.9) and poorly soluble (< 12 Pg/mL, aqueous
pH 7) inhibitor of one of the phosphatidylinositol-3-kinases (PI3KG), which is implicated in the
pathology of asthma and chronic obstructive pulmonary disease.
10
Phosphatidylinositol-3-kinases are lipid kinases whose role is to phosphorylate the 3-position hydroxyl
of phosphatidylinositides. Eight different kinases are known, of which the class IA subgroup (the D-,
E-, and G- isoforms) generates phosphatidylinositol-3,4,5-triphosphate. Interest in PI3K inhibitors has
been intense in recent years, and around 20 compounds (with varying degrees of selectivity for the
various isoforms) are currently in clinical development.
11
For example, PI3KD inhibitors are being
progressed as potential anti-cancer agents.
11
The students work on a research programme that is live at GSK. They do not work on the structural
series being pursued by GSK (and any intellectual property which results from the module is owned
by the University of Nottingham), but this allows the students to feel they are connected to an ongoing
effort to discover a new medicine for treating severe asthma.
A primary focus is to progress the molecular series towards an improved drug-like profile (as opposed
to results for publication) by paying close attention to physicochemical properties alongside potency.
The project was specifically designed to ensure the students experienced two iterations of the
analyse-design-synthesis-test cycle
12
 pivotal learning points in medicinal chemistry  despite the
inexperience of the students and the very limited time available. There are three stages. Firstly, the
students devise two arrays of twenty target compounds; one consisting of amine derivatives (2)
(which should help improve aqueous solubility) and the other of substituted aryl derivatives (3) (to
improve potency)( Figure 1). Lists of the building blocks (or monomers) used in the target compound
arrays can be found in Figures 2 and 3.
Consideration of lipophilicity, molecular weight, and hydrogen bond donor/acceptor count (Lipinskis
Rule of Five)
13
drives the selection of amines, whereas the aryl derivatives are selected by interactive
visualisation on the basis of their fit and potential interactions suggested from dockings into the
enzyme binding site,
14
derived from the parent structure established by X-ray crystallography.
15
Rotations about the pyrimidine  aryl bond are also evaluated in conjunction with a potential energy
plot, to determine whether other attractive, low-energy binding modes exist. Calculated logP and
molecular weight data are also considered. Figure 4 shows compound 1 docked into the ATP binding
site of PI3KG. The students find the assimilation of the wealth of data quite challenging, as they have
to design their arrays in only a one-hour workshop. The presence of an experienced medicinal
chemist with each group during its deliberations is important to ensure logical and not random choices
are made. In the case of the amine analogues, presentation of their properties through a Spotfire
plot
16
(see Figure 5) is particularly useful for visualising the chemical space. For example, initial
choices could be marked on the plot to ensure an adequate diversity of structure in the array, and, if
necessary re-examined before settling on the final array. The compound arrays have already been
prepared by scientists at GSK, so the screening results (inhibition potency vs. PI3KG (pIC50),17
aqueous solubility
18
and measured logD
19
) are available to the students in time for the next workshop
and round of design.
Figure 1
First round of optimisation
Second round of optimisation  phenol with various amine combinations.
Third round of optimisation  replacing the phenol with heterocyclic isosteres
Palladium catalysts used in the Suzuki reaction.
Figure 2. Amine building blocks (monomers) used for the synthesis of 2.
Figure 4. The reference binding mode for compound 1
was obtained from the crystal structure 2WXP.
15
The
binding site has been surfaced and the hydrophobic
(green) and polar (purple) interaction potentials were
mapped by using MOE
14
to help identify features of
interest in the binding site and to indicate where it might
be possible to make new interactions with the receptor.
Figure 3. Building blocks (monomers), as boronic acids, used for the synthesis of 3.
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In the second stage, analysis of the screening data clearly reveals the phenol 4 (Figure 6) as the best
aryl derivative, since it increases potency by approximately 100-fold, though solubility is practically
unchanged compared with compound 1. Interpretation of the results from the amines is less clear-cut
as there is a spread of potency and solubility; students are asked to select one amine derivative each
(5) to make in conjunction with the meta phenol group substituent (Figure 1). From a table of data
hydroxy amines and diamines stand out as substituents that not only enhance solubility but also
potency (up to 10-fold) whilst targeting an attractive logD range (2  3.5). At this stage the teams
prepare and deliver a presentation of their results so far and their plans for the compounds they will
prepare in the laboratory.
Figure 6.
Lastly, in the final workshop, the students are presented with a further challenge. They are informed
that the phenol may be good for potency, but it is a group with susceptibility to rapid metabolism, so it
would be prudent to prepare some bio-isosteres of the phenol.
20,21
Thus, by examining the fit of a set
of heterocyclic analogues in the enzyme active site, clogP values and using the Rule of Five, the
students plan to make further target compounds (6) that combine the best amine and heterocyclic
groups (Figure 1).
Each team then proceeds to carry out their synthesis plans in the laboratory. They have 40 hours
laboratory time, spread over four weeks. During this time, each team typically attempts the
preparation of around fifteen target compounds. As the teams select targets independently of each
other, some targets appear in more than one teams plans.
The way in which the teams are selected and coached deserves comment. Teamwork is emphasised
strongly as it is so important for success in the pharmaceutical industry. Part of one workshop is
devoted to describing how effective teams are assembled. To do this we employ the Belbin Team
Role questionnaire
22
which helps identify preferred ways of working in teams. This allowed the
students to develop increased self-knowledge and a clearer appreciation of their strengths and
weaknesses, which can then feed into organisation of their presentations and laboratory activities.
Each team is selected to have a blend of the nine characteristics. In addition, we take into
consideration gender and academic ability. Teams are also encouraged to develop a relationship
with the industrial mentors that is distinct from the usual student-academic one in which assessment
provides a backdrop. Students welcome the opportunity to ask about applied research and careers in
industry. Indeed, one student from the 2010 group is now employed by GSK, after completing a
successful summer internship.
The section below provides a more detailed description of the chemistry. Once the compounds have
been made and characterised, they are sent for screening at GSK. The results are returned to the
students for incorporation into individual reports which form part of the formal assessment. The
reports are about eight pages long and follow the general structure of a paper from Bioorganic and
Medicinal Chemistry Letters. This gives the students the opportunity to demonstrate their
understanding of the project, its objectives and to what extent the compounds they made moved the
project towards those objectives.
Target Compound Synthesis and Screening Results
The project chemistry was designed to permit rapid synthesis of a wide range of target compounds.
Thus, intermediate aldehydes 7
23
and 10
24
that are not commercially available were prepared and
donated by GSK. The project provides a showcase for two mechanistically important reactions
frequently employed in the pharmaceutical industry: reductive amination
25
and the Suzuki-Miyaura
reaction
26
for biaryl coupling. Preliminary investigations of the chemistry by GSK following the
procedures described by Folkes et al.
23
revealed some problems. Consequently, in order to give the
best chance for many analogues to be completed, the students are provided with modified reaction
procedures, and are not encouraged to vary them. Thus, in the reductive amination to make phenol
derivatives 5, the phenol is protected with a tert-butyldimethylsilyl group as it leads to faster reactions.
The reduction is achieved with sodium triacetoxyborohydride in chloroform because 1,2-
dichloroethane was deemed too hazardous. The various amines chosen by the students (8 a-o) are
shown in Table 1. The intermediate 9 is desilylated, conveniently and rapidly, with ammonium
fluoride
27
and then purified by column chromatography to give 5. Table 1 shows the analogues
prepared (with screening data).
In a similar manner, reductive amination of 10, typically on 0.75  1.0 g scale, with selected amines
(about three per team) gives stocks of intermediate chloropyrimidines, sufficient for several Suzuki
coupling reactions with various boronic acids (11 a-l) (Figure 7) on 0.25 mmol scale. Two sets of
reaction conditions, with different palladium catalysts 12 and 13 (Figure 1) under microwave heating,
can be used (for full details see Experimental Section). Conditions with conventional heating have not
been investigated. The advantage of catalyst 12 is shortened reaction times. Following work-up, the
products 6 are purified by column chromatography. Table 2 shows analogues prepared (with
screening data).
Figure 7. Boronic acids (HetB(OH)2) used in the Suzuki reaction.
Table 1. Phenol analogues prepared, with screening results.
Comp. Amine R
1
R
2
N Yielda (%) pIC50 BEIb Solubilityc logD7.4
5a
8a
47, 21 6.9 17.4 ++ 2.7
5b
8b
58, 53, 39,
21,16, F
8.9 18.8 +++ 2.0
5c
8c
59, 42, 33, 17 8.1 18.5 ++ 1.3
5d Me2NCH2CH2NMe 8d 61, 60, 33, 22 7.9 18.5 +++ 1.2
5e HOCH2CH2NH 8e 11, 9, F 7.6 19.7 +++ 1.2
5f HOCH2CH2NMe 8f
63,
d
58,
d
39,
d
20, F, F, F
7.9 19.7 +++ 1.7
5g CH3CH2CH2NH 8g 53 7.3 19.0 ++ 2.4
5h
8h
69,
d
16, 9 7.4 18.6 ++ 1.3
5i
8i
24, 31, 39 7.7 18.1 ++ 2.1
5j
8j
57, 33, 10, F 8.6 19.6 +++ 1.6
5k
8k
24 8.2 17.6 ++ 2.3
5l
8l
78, 59, 51, 44 8.3 17.7 ++ 1.9
5m
8m
40 8.3 17.2 +++ 1.2
5n
8n
46
e
7.8 18.3 +++ 1.3
5o
8o
71
e
7.2 17.4 ++ 1.3
a
: Yields: each figure corresponds to a separate experiment; F corresponds to a failed reaction in which no
product was successfully isolated following chromatography. All compounds are solids and were characterised
by melting point,
1
H NMR and IR spectroscopy. In addition, all compounds tested by GSK underwent quality
DVVHVVPHQWE\/&06DQGDOOZHUHGHWHUPLQHGWREHSXUHb: BEI = binding efficiency index = pIC50 u
1000 / MW, see Abad-Zapatero, C.; Expert Opin. Drug Discov. 2007, 2, 469-488.
c
: Compounds were ranked as
+++ (soluble, >100 Pg/mL), ++ (poorly soluble, 10  100 Pg/mL), and + (very insoluble, <10 Pg/mL). d: Yield
improved by using 5 equivalents of amine.
e
: Reductive aminations were performed with 2-(N-Boc-
aminomethyl)pyrrolidine (8n) and N-Boc-N-ethyl-1,2-diaminoethane (8o). After desilylation and purification, the
Boc group was removed by treatment with 4N hydrogen chloride in dioxane at 0 qC.
Table 2: Heterocyclic analogues prepared with screening results.
Comp. R
1
R
2
NH Het Yield %
a
(Method) pIC50 BEI
b
Solubility
c
logD7.4
6a 8a 11a 5 (A) 6.9 16.4 ++ NA
6b 8b 11a
78 (A)
31 (A)
57 (B)
20 (B)
7.8 15.9 ++ 2.0
6c 8c 11a
52 (A)
58 (A)
8 (A)
7.5 16.7 +++ 1.3
6d 8d 11a
45 (A)
27 (A)
13 (A)
7.1 15.7 ++ 1.3
6e 8f 11a
50 (A)
42 (A)
12 (B)
6.9 16.2 ++ 1.7
6f 8h 11a 51 (A) 6.4 15.2 ++ 1.4
6g 8i 11a
21 (B)
8 (B)
7.7 15.6 +++ 2.0
6h 8j 11a
41 (A)
8 (B)
5 (A)
7.7 16.4 ++ 1.7
6i 8l 11a
8 (B)
22 (B)
7.8 15.8 +++ 2.0
6j 8b 11b 37 (B) 6.6 13.0 +++ 2.6
6k 8j 11b
9 (A)
F (A)
6.2 13.3 ++ 2.2
6l 8a 11c 27 (A) 5.4 12.9 + 2.7
6m 8j 11c F (A)
6n 8b 11d 53 (A) 6.8 13.8 + 2.9
6o 8c 11d F (A)
6p 8j 11d 10 (A) 6.4 13.8 ++ 2.6
6q 8b 11e 24 (A) 6.2 12.2 +++ 1.7
6r 8c 11e F (A)
6s 8d 11e 15 5.8 12.4 +++ 1.1
6t 8j 11e
13 (A)
79 (A)
19 (B)
39 (B)
F (A)
6.3 13.2 +++ 1.5
6u 8l 11e 30 (B) 6.1 12.9 +++ 1.7
6v 8c 11f F (A)
6w 8j 11f 59 (A) <4.5 <9.6 +++ NA
6x 8c 11g F (A)
6y 8d 11g
27 (A)
F (A)
6.9 15.3 + 1.6
6z 8j 11g F (A)
6aa 8c 11h 5 (A) 6.6 13.9 +++ 2.6
6ab 8a 11i F (A)
6ac 8b 11i
15 (B)
7 (A)
6.3 12.8 ++ 2.6
6ad 8c 11i 29 (A) 6.2 13.4 +++ 1.9
6ae 8d 11i
48 (A)
9 (A)
7.1 15.8 ++ NA
6af 8h 11i 23 (A) 5.5 13.0 ++ 1.9
6ag 8j 11i 14 (A) 6.0 13.0 ++ 2.3
6ah 8l 11i 11 (B) 5.9 12.0 +++ 2.6
6ai 8m 11i 2 (B) 5.9 11.7 +++ NA
6aj 8b 11j F (A)
6ak 8j 11j F (A)
6al 8d 11k 18 (A) 6.7 14.9 +++ 1.1
6am 8f 11k 50 (A) 5.5 13.0 +++ 1.7
6an 8h 11k 8 (A) 6.1 14.5 ++ 1.1
6ao 8d 11l 8 (A) 7.7 18.0 +++ 0.6
6ap 8c 11l 9 (A) 7.9 18.0 ++ 0.7
6aq 8f 11l 8 (A) 7.2 18.0 ++ 1.0
a
: Yields: each figure corresponds to a separate experiment; F corresponds to a failed reaction in which no
product was successfully isolated following chromatography. All compounds are solids and were characterised
by melting point,
1
H NMR and IR spectroscopy. In addition, all compounds tested by GSK underwent quality
DVVHVVPHQWE\/&06DQGDOOZHUHGHWHUPLQHGWREHSXUHb: BEI = binding efficiency index = pIC50 u
1000 / MW.
c
: Compounds were ranked as +++ (soluble, >100 Pg/mL), ++ (poorly soluble, 10  100 Pg/mL), and
+ (very insoluble, <10 Pg/mL).
To ensure experiments are conducted safely, the following precautions are taken. Students wear
standard personal protective equipment (lab coats, safety spectacles and gloves) and conduct all
reactions and work-ups in a fumecupboard. The hazards associated with the aldehydes 7 and 10 and
boronic acids have not been established, but standard precautions are adequate to limit exposure.
The hazards associated with the other chemicals are listed in the Experimental. Certain chemicals,
particularly dioxane and chloroform, are undesirable owing to their toxicity and environmental impact,
and efforts are being made to eliminate them through modification of the experimental protocols.
Demonstrators instruct the students in setting up the Suzuki reactions in microwave vials, in particular
to ensure all solids are below the level of the solvent. The demonstrators are responsible for sealing
the vials and operating the microwave reactors.
Resources
GSK committed substantial resources in setting up the course. These included selecting the
appropriate live in-house programme, the appropriate molecular template for inhibiting PI3KG which
allowed iterative cycles of medicinal chemistry, choreographing the iterations to fit the time available,
development of robust synthetic chemistry procedures and purification protocols, bulk synthesis of
intermediates for the students to use, the synthesis and testing of large numbers of compounds so
that data can be rapidly provided to the students after various iterations, the preparation of material to
be taught in workshop modules, molecular modelling visualisations of potential targets in the active
site, data analysis visualisation plots, and multiple visits for mentoring the students. Each GSK
mentor for example, spent approximately 1-2 weeks preparing and then another week teaching and
mentoring. To date, over 20 employees at GlaxoSmithKline in Stevenage have contributed.
Discussion
Extensive informal feedback was obtained from the students through individual conversations. They
particularly appreciated the problem-based approach, especially as it so sharply contrasted with their
laboratory experience from the previous year. Other aspects that drew favourable comments were
that theory was linked to practice and a real-life problem, and the significant input from scientists from
industry. The students found the team skills training interesting and not like anything they had
experienced before  they discovered that success is not just about academic ability  which gave
personal insights into what qualities potential employers might expect. It was interesting to observe
that, despite the process to assign students to teams, not all teams performed equally well. Those
that did some planning ahead of each practical session (independently of a tutor or demonstrator)
were generally better organised and able to make the best use of their time in the laboratory. Aspects
of the course workshops, such as discussion and practicing concepts (calculating hydrophobicities,
molecular modelling) immediately helped cement learning.
The following are quotes from students, taken from the Universitys Student Evaluation of Module and
Teaching forms.
The best part of the module was being taught by people who have extensive experience in the
pharmaceutical industry; this was beneficial as they often related new material to projects they had
worked on previously.
I really enjoyed how the module combined everything we had learnt in lectures to allow us to see and
be part of the drug discovery process. I believe it gave a real insight into medicinal
chemistry/pharmaceutical industry, through practical drug development and seeing how drugs get to
market, and showed us what we could achieve after leaving university. I thoroughly enjoyed the
module and would recommend it to any aspiring medicinal chemist.
What I liked about the GSK module is that it brought my degree into practice and helped bring the
pharmacological aspects that we had studied together with the chemistry. I think the module could
have been improved by having more time in the design process of compounds.
Really enjoyable module, made me want to do my 4
th
year project in medicinal chemistry.
Very engaging, lots of advice and support, excellent notes, good fun.
Free-thinking encouraged.
The interactive workshops challenged thought processes.
It allows me to put the theory learnt into practice. Conducted in small groups increasing teamwork
and communication skills.
Made you think. Relevant to drug design.
Loved having actual researchers from industry, made the module interesting and enjoyable.
I like the variety of assessments types. I think the link with the lab modules is very good because it
enables a better idea of the practical issues facing medicinal chemists.
The workshops were well structured and encouraged participation. The relevance to the real world
also helped retain my interest.
I enjoy working in a team, and it was nice working with people I haven't worked with before. It was
also really good having speakers coming in from GSK and the mentors were brilliant at providing
assistance and willing to answer questions.
What has the GSK staff learnt and how do they feel they have benefited? Several clear themes
emerge:
x Most GSK staff particularly enjoyed the interactions with the students. Several of the GSK
mentors felt they developed more effective time management skills based on juggling both
their GSK and Nottingham workloads.
x Many were struck by the challenge of delivering the aims of the module to inexperienced
students in the very limited timeframe. Other challenges included (i) preparing (and
sometimes relearning!) the teaching material at the right level, (ii) requiring the students to
prepare pure, characterised and some cases novel compounds for test and (iii) learning how
to coach the student teams in decision making, and to manage group dynamics.
x Thinking about the best way to present the results from the various iterations to the students
also made one mentor think carefully about how to present data most effectively at GSK.
x Everyone involved from GSK was surprised how clearly the course aims and scope were
expected to be. For example, it was essential that examinable and non-examinable material
was made explicit.
Chemistry achievements and challenges
Considering the scientific achievements of the course, most of the experiments were successful, and
students were able to isolate good quality samples. Some of the yields were rather low, which was
probably due to student inexperience. Failures in the reductive aminations could be attributed to
difficulties in dispensing accurately small quantities of liquid amines (Gilson pipettes were used), and
the unreactive nature of some of the amines (particularly the amino alcohols). The main side product
was the primary alcohol 14 (Figure 6), which sometimes misled students into thinking this was the
desired product, though NMR readily identified it. Yields for the reductive aminations on 2-3 mmol
scale were invariably higher than those on 0.3 mmol. The literature suggests improved yields might
be expected with sodium cyanoborohydride in methanol,
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but this was considered too hazardous for
undergraduates. The first time the project was run, some protected diamines e.g. 8n, 8o were
included. While the reactions worked, the extra step involved in removing the protection made the
overall procedure very long, though feasible for more able students. Some of the students
responded very positively to the challenge of a failed reaction and discussed how conditions might be
altered before putting the reaction on again. Exposure to industry-standard equipment (microwave
reactors, automated chromatography) and methodology was welcomed.
The
1
H NMR spectra of the target compounds were challenging to interpret due to three features
sometimes present. Firstly, the relatively slow bond rotation of the morpholine ring (and piperazine
ring, where present) sometimes caused signal broadening. Signal broadening was also observed
with the hydrochloride salts of certain derivatives. Finally, derivatives of the tertiary amide 8b
displayed two sets of signals in an unequal ratio owing to slow rotation about the amide bond. Most
of the students were unfamiliar with these concepts from their lecture courses.
The two methods for the Suzuki coupling worked as well as each other; catalyst 12 is more active but
also more expensive than 13. More failures were observed than with the reductive amination: they
seemed to be more related to the boronic acid selected, though this was difficult to be sure about.
On average each student performed five reactions, three chromatographic separations, and
succeeded in making two test compounds. The students medicinal chemistry reports were generally
very well written, demonstrating good understanding of the project objectives, though some had
difficulty with correct use of the scientific terminology and ensuring accurate drawing of chemical
structures.
Some of the compounds possessed significantly improved profiles compared with compound 4 (pIC50
= 7.7). In particular, the pyrrolidines 5b and 5c, and piperazines 5j - 5m combined pIC50 values >8
with much improved aqueous solubility and reduced lipophilicity (logD in the range 1.3  2.3). The
best of these was the tertiary amide 5b, although 5j has the best combination of potency and binding
efficiency index. It is of note that 5f is almost as potent and has the equal highest BEI, suggesting
that derivatives might be worth investigation. From the wide range of phenol bioisosteres examined,
the ones with a 1H-indazol-4-yl group, in combination with the preferred amines (6b, 6c, 6h and 6i)
were clearly the most potent, though none of them could quite match the potency of the
corresponding phenols. However, good aqueous solubility was achieved whilst maintaining a drug-
like logD. Only one 1H-indol-4-yl analogue (6y) was prepared successfully, and possessed similar
potency to 6d, suggesting that further analogues should be made. However, azaindoles 6al-6an
were disappointing. In contrast, compounds based on isomeric indazoles (11c, 11d) or N-methyl
heterocycles (11b, 11h) possessed modest potency and were also some of the most lipophilic
compounds made (logD7.4 >2.5). Very interesting results were obtained with the aminopyrimidines
6ao and 6ap, which achieved good potency and BEI at very low lipophilicity. Incorporation of this
heterocycle into further derivatives would permit a search for more potency through more lipophilic
amines, without departing from the ideal logD range or increasing the molecular weight beyond 500,
as has recently been described by Genentech-Piramed.
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It is interesting that, as yet, none of the students have proposed making GDC-0941 (Figure 6),
23
which was the PI3KD inhibitor taken into development. This is because the sulfonylpiperazine does
little to improve aqueous solubility and is thus an unattractive choice of amine. GDC-0941 also
breaks Lipinskis molecular weight rule and has ten hydrogen bond acceptors. What cannot be
predicted is that, whereas the 1H-indazol-4-yl compound in most cases is less potent than the
corresponding phenol analogues, in the case of the sulfonylpiperazine analogue potency is fully
retained.
23,30
Conclusions
The development of a practical medicinal chemistry course, suitable for third-year undergraduates,
has been described. Students have learnt about balancing three important properties  potency,
solubility and lipophilicity  and have successfully designed more potent and soluble analogues such
as 5b, 5j, 6b, 6c, 6h, 6i, 6ao and 6ap.
It is evident that other universities may not be able to reproduce this project without the same level of
funding, access to equipment and screening facilities. However, one might be able to take it as a
template, consisting of:
x An enzyme target with a published X-ray crystal structure, with a way to conduct molecular
modelling and docking of target compounds.
x A simple assay for enzyme inhibitors with commercially available enzyme and fluorogenic
substrate. Aqueous solubility can be measured by eye (turbidometric method), and the
hydrophobicity index requires access to an analytical hplc with reverse-phase column.
x A lead chemical series with opportunities for derivatisation through 1-3 chemical steps. Key
intermediates should be commercially available or readily synthesised.
Since the current module is limited to eighteen chemistry students, consideration is now being given
to devising alternative projects that would be less expensive, less reliant on industry support (e.g. for
intermediates and compound screening), and potentially open to more students.
Experimental
General experimental. Spectroscopic data were recorded on Bruker Tensor 27 IR and Bruker
AV400 (
1
H NMR 400 MHz), Bruker DPX300 (
1
H NMR 300 MHz), Jeol EX270 (
1
H NMR 270 MHz)
instruments. All reactions were conducted under a positive pressure of dry nitrogen unless stated
otherwise. Amines 8 a-m and boronic acids 11a-l were obtained from commercial sources. Amines
8n and 8o were purchased as their N-Boc derivatives. Compounds 7 and 10 were prepared by GSK
according to the methods of Folkes et al.
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Palladium catalysts 12 and 13 were purchased from
Sigma-Aldrich and Alfa Aesar, respectively. Column chromatography was performed on silica gel or
aminopropyl-modified silica gel (Biotage Isolute or SNAP cartridges) with a Jones
Chromatography Flashmaster II automated system. Kieselgel 60 F254 plates from E. Merck and
aminopropyl-modified plates from Biotage were used for TLC, and compounds were visualised using
u.v. light, anisaldehyde solution or 0.5% aqueous potassium permanganate solution. Petrol refers to
petroleum ether (bp 4060qC) unless stated otherwise.
Hazards
Chloroform is an irritant and harmful if ingested. It also is a cancer suspect agent in humans (IARC
class 2B). Dioxane is an irritant, highly flammable, may form explosive peroxides. It also is a cancer
suspect agent. Acetic acid is corrosive and flammable. Ethanol is flammable. Toluene is flammable
and an irritant and may cause lung damage if ingested. It is also a potential teratogen. Sodium
triacetoxyborohydride may liberate hydrogen gas in the presence of water. Ammonium fluoride is
toxic on skin contact, inhalation or if ingested. Potassium phosphate is a skin irritant and may cause
serious eye damage. The various amines used in the project are flammable and corrosive  further
information on their hazards may be obtained from commercial suppliers. The palladium catalysts, 2-
(dimethylaminomethyl)ferrocen-1-yl-palladium (II) chloride dinorbornylphosphine complex (12) and
PdCl2(PPh3)2 (13), do not have hazards listed  however, they should be assumed to be toxic.
Procedure for reductive amination of aldehyde (7) followed by desilylation. 2-(3-((Tert-
butyldimethylsilyl)oxy)phenyl)-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde (152 mg, 0.33
mmol) was dissolved in chloroform (5 mL) under nitrogen at room temperature. The amine 8 (0.66
mmol) and acetic acid (0.5M in chloroform, 1.32 mL, 0.66 mmol) were added and the resulting
solution was stirred for 15-30 minutes. Sodium triacetoxyborohydride (210 mg, 0.99 mmol) was then
added as a solid in one portion, and the reaction mixture was stirred until tlc indicated complete
reaction (between 30 min and 16 h). Saturated aqueous sodium bicarbonate (10mL) was added to
the solution and the organic layer separated. The aqueous layer was extracted with chloroform (10
mL) and the combined organic solutions were dried (MgSO4) and concentrated under reduced
pressure to give the crude amine silyl ether 9.
The crude silyl ether 9 (assumed to be pure, 1.0 equiv.) was treated with a solution of ammonium
fluoride (5.0 equiv.) in methanol (5-10 mL/mmol silyl ether) under nitrogen at room temperature. The
mixture was stirred until tlc indicated complete reaction (typically < 30 min). The solvent was removed
under reduced pressure and the residue was taken up in 1-2 ml dichloromethane (some ammonium
fluoride did not dissolve). The solution was then applied to the top of a Biotage Isolute silica gel
cartridge (20 g) and eluted using the Flashmaster apparatus (gradient elution with hexane/ethyl
acetate/methanol/triethylamine or dichloromethane/methanol/ammonia). Fractions containing product
were identified by tlc, and evaporated under reduced pressure to give the product. For those
products that were not obtained as solids, treatment with a small volume of hot ethyl acetate and
scratching caused the product to crystallize. The suspension was filtered and dried to give the
desired product 5.
Alternatively, the desilylation step could be performed by using a solution of tetrabutylammonium
fluoride in THF (1.1 eq.) at room temperature.
For those amines that were purchased as the hydrochloride salts, the acetic acid was omitted and
replaced by a molar equivalent amount of anhydrous sodium acetate.
Data for 6-hydroxymethyl-2-(3-hydroxyphenyl)-4-morpholinothieno[3,2-d]pyrimidine (compound 14):
1
H NMR (270MHz, DMSO-d6) GH 9.49 (1H, s), 7.84 (1H, s), 7.83 (1H, d, J 8 Hz), 7.31 (1H, s), 7.26
(1H, t, J 8 Hz), 6.24 (1H, d, J 8 Hz), 5.91 (1H, t, J 5.7 Hz), 4.85 (2H, d, J 5.7 Hz), 3.98 (4H, m), 3.80
(4H, m).
Preparation of heterocyclic derivatives (6) via Suzuki reaction.
The procedure for reductive amination of chloropyrimidine (10) is the same as above, omitting the
desilylation step, but was generally conducted on 2.5-3.5 mmol scale.
Suzuki reaction Method A: The chloropyrimidine (0.25 mmol, 1.0 equiv.), boronic acid (11) (0.375-
0.5 mmol), and potassium phosphate (3.0 equiv.) were weighed into a microwave vial equipped with a
stir-bar at room temperature. The catalyst, 2-(dimethylaminomethyl)ferrocen-1-yl-palladium (II)
chloride dinorbornylphosphine complex (0.1 equiv.) was added. Then a mixture of dioxane and water
(2:1, 4 ml/mmol of chloropyrimidine) was added carefully and the vial was flushed with nitrogen. The
vial was sealed and heated in a microwave reactor for 10 min at 140qC. The cooled reaction mixture
was sampled by tlc (silica gel and aminopropyl silica gel) and if the reaction was not complete,
another 1 equiv. boronic acid/ester added, and reaction continued for another 10  20 min at 140qC.
The mixture was filtered through a pad of kieselguhr, washing with ethyl acetate (10 ml). The filtrate
was washed with saturated aqueous sodium bicarbonate (5 mL), dried (MgSO4) and the solvent was
removed under reduced pressure. The residue was taken up in ~1 mL dichloromethane and applied
to the top of an aminopropyl silica gel cartridge (10 or 20 g) and eluted using the Flashmaster
apparatus (gradient elution with hexane/ethyl acetate/methanol; typically 0  100% ethyl acetate in
hexane over 15 min followed by 0  15% methanol in ethyl acetate over 15 min, flow rate 15 - 20
mL/min). Fractions containing product were identified by tlc, and evaporated under reduced pressure
to give the product as a gum. Treatment with a small volume of hot ethyl acetate and scratching
caused the product to crystallize. The suspension was filtered and dried to give the desired product
(6). Occasionally, products that refused to crystallise were converted to their hydrochloride salts in
order to obtain a solid sample.
Suzuki reaction Method B: The chloropyrimidine (0.22 mmol, 1.0 equiv.), boronic acid (11) (0.44
mmol), and sodium carbonate (0.77 mmol, 3.5 equiv.) were weighed into a microwave vial equipped
with a stir-bar at room temperature. The catalyst, bis(triphenylphosphine)palladium (II) chloride (0.02
mmol, 0.1 equiv.) was added. Then toluene (1.2 mL), ethanol (0.6 mL) and water (0.3 mL) were
added carefully and the vial was flushed with nitrogen. The vial was sealed and heated in a
microwave reactor for 90 min at 130qC. Work-up and purification was as described above.
Compound assays
Methods for measuring PI3KG inhibitor potency, aqueous solubility and logD by hplc are described in
references 17-19, respectively.
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Figure 5. Spotfire plot (molecular weight vs. clogP) for the array of amines. Each spot corresponds to a different target compound (amines A01  A42), with
the spots shape and colour coded according to the number of hydrogen bond acceptors and donors, respectively. Students discuss target choice in relation
to Lipinskis Rule of Five.
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